AI is a bubble | Weave Bio
Summary
Weave Bio raised $20M in Series A funding to scale its AI-native regulatory workflow platform for drug developers. The company says its software speeds regulatory timelines by more than 50% across stages from Pre-IND through post-market. The platform combines AI with human validation to improve speed, accuracy, and compliance. The company plans to expand globally and serve more life sciences teams. The message positions the product as practical software for a major pharma bottleneck rather than as generic AI hype.
Funding
Amount
$20.0M
Total raised
Date
October 16, 2025
Announcement date
Investors
U.S. Venture Partners, Innovation Endeavors, Magnetic Ventures
Lead investors
Company
https://www.weave.bio
Funded company
Classifications
industries
No industries detected
applications
Data Management
AskAI Classifications
Labels
SaaS
RegTech
AI Software
Linked Companies
Weave
$1M to $5M